Kursinformation
Aktuelle News
News Funktionen
Weitere Funktionen
20 März 2024
Secarna Pharmaceuticals GmbH & Co. KG
Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies
3 November 2023
Secarna Pharmaceuticals GmbH & Co. KG
Secarna Pharmaceuticals presents data at SITC demonstrating the potential of antisense oligonucleotides in targeting NRP1
25 Oktober 2023
Secarna Pharmaceuticals GmbH & Co. KG
Secarna Pharmaceuticals presents data at OTS showcasing unique characteristics and factors with a role in the activity and side effect profile of LNA-modified ASOs
17 Oktober 2023
Secarna Pharmaceuticals GmbH & Co. KG
Secarna Pharmaceuticals to present two posters showcasing the innovation potential of the LNAplus platform at the 19th Annual Meeting of the Oligonucleotide Therapeutic Society
6 Juli 2023
Secarna Pharmaceuticals GmbH & Co. KG
Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in debilitating autoinflammatory diseases
5 Juni 2023
Secarna Pharmaceuticals GmbH & Co. KG
Secarna Pharmaceuticals announces publication of new preclinical data showing durable antitumor activity of LNAplus™-based ASOs that both stimulate the innate immune system and suppress PD-L1 expressi